The global Dupuytren's disease market relies majorly on surgical interventions and drugs for treatment. Dupuytren's disease is a medical condition characterized by formation of fibrous cords and nodules under the skin of the palm, which causes fingers to bend towards the palm permanently over the time. Non-surgical treatments such as needle aponeurotomy and collagenase injections are preferred line of treatments owing to their less invasiveness.

The global Dupuytren's disease market is estimated to be valued at US$ 4.3 Bn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period from 2024 to 2031.

The Global Dupuytrens Disease Market Trends can be attributed rising prescription volumes of branded drugs for disease management. Development of recombinant and biosimilar drugs can lead to new treatment opportunities that favor market growth. Key players like Endo International Plc, Bristol-Meyers Squibb Company, and Spear Pharmaceuticals offer drugs for disease treatment that drive overall prescription volumes. Global expansion of key companies to emerging regions will boost the regional market size over the forecast period.

Key Takeaways

Key players operating in the global Dupuytren's disease market are Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG, Bayer AG, Novartis AG, Pfizer Inc., Nantong Jinghua Pharmaceutical Co., Ltd., and Actiza Pharmaceutical Pvt. Ltd., 180 Life Sciences Corp.

Key opportunities in the market include development of novel therapeutics such as recombinant collagenase injections and biosimilars. This along with clinical trials for pipeline drugs will help expand the treatment landscape for disease management.

Globally, companies are expanding their operations in high growth markets such as Asia Pacific and Latin America through partnerships and acquisitions. This allows them to tap unmet needs and boost sales volumes in emerging countries.

Market Drivers

Rising prescription volumes of branded drugs for disease management is a key driver. Developed markets see higher prescription rates for branded drugs compared to generics. This positively impacts the revenue growth of key players.

Market Restraints

Expiry of patents of blockbuster drugs reduces profit margins of companies. Additionally, pricing pressure due to market entry of biosimilars poses a major challenge. Stringent regulations for drug approvals further delay market entry of novel therapies.

Segment Analysis

The Global Dupuytren's Disease Market is dominated by the diagnostics segment which is expected to possess a market share of 44.3% in 2024. This is due to the growing number of patients opting for radiographic testing such as x-ray or MRI for early diagnosis of the disease. Within diagnostics, imaging testing sub-segment holds the largest market share owing to advantages such as non-invasive nature and ability to detect the disease at earlier stages.

The treatment segment is further categorized into drug therapy, surgery, and other therapies. The surgery sub-segment presently dominates the overall treatment segment attributed to increasing preference of patients and physicians for surgical intervention to correct finger contractures caused by Dupuytren's disease.

Global Analysis

Regionally, North America held the largest share of the global Dupuytren's disease market in 2024 and is expected to grow at a CAGR of 4.0% during the forecast period. Factors such as advanced healthcare infrastructure, rising patient awareness about the disease, and new product launches by key players drive the market growth. On the other hand, Asia Pacific is projected to experience the fastest growth rate over the forecast years owing to increasing per capita healthcare expenditure and growing medical tourism in countries like India and China.

Europe captured the second largest market share in 2024 and is likely to maintain its position through 2031. Key growth determinants in the region include well-established reimbursement policies and continual research for enhanced treatment options.

Get More Insights On- Global Dupuytrens Disease Market